NL8204122A - Met gamma-cyclodextrine gevormde insluitingscomplexen van steroideverbindingen, werkwijze voor de bereiding ervan, alsmede geneesmiddelpreparaten welke deze insluitingscomplexen bevatten. - Google Patents

Met gamma-cyclodextrine gevormde insluitingscomplexen van steroideverbindingen, werkwijze voor de bereiding ervan, alsmede geneesmiddelpreparaten welke deze insluitingscomplexen bevatten. Download PDF

Info

Publication number
NL8204122A
NL8204122A NL8204122A NL8204122A NL8204122A NL 8204122 A NL8204122 A NL 8204122A NL 8204122 A NL8204122 A NL 8204122A NL 8204122 A NL8204122 A NL 8204122A NL 8204122 A NL8204122 A NL 8204122A
Authority
NL
Netherlands
Prior art keywords
cyclodextrin
steroid
complex
solubility
water
Prior art date
Application number
NL8204122A
Other languages
English (en)
Dutch (nl)
Original Assignee
Richter Gedeon Vegyeszet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Vegyeszet filed Critical Richter Gedeon Vegyeszet
Publication of NL8204122A publication Critical patent/NL8204122A/nl

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/001—Lactones
    • C07J21/003—Lactones at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nanotechnology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NL8204122A 1981-10-27 1982-10-26 Met gamma-cyclodextrine gevormde insluitingscomplexen van steroideverbindingen, werkwijze voor de bereiding ervan, alsmede geneesmiddelpreparaten welke deze insluitingscomplexen bevatten. NL8204122A (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU813147A HU190356B (en) 1981-10-27 1981-10-27 Process for preparing steroid-gamma-cyclodextrin inclusion complexes with high water-solubility
HU314781 1981-10-27

Publications (1)

Publication Number Publication Date
NL8204122A true NL8204122A (nl) 1983-05-16

Family

ID=10962794

Family Applications (1)

Application Number Title Priority Date Filing Date
NL8204122A NL8204122A (nl) 1981-10-27 1982-10-26 Met gamma-cyclodextrine gevormde insluitingscomplexen van steroideverbindingen, werkwijze voor de bereiding ervan, alsmede geneesmiddelpreparaten welke deze insluitingscomplexen bevatten.

Country Status (12)

Country Link
JP (1) JPS5883699A (da)
BE (1) BE894825A (da)
DD (1) DD208549A5 (da)
DE (1) DE3238800A1 (da)
DK (1) DK474782A (da)
ES (1) ES8308571A1 (da)
FR (1) FR2515187A1 (da)
GB (1) GB2109381A (da)
HU (1) HU190356B (da)
IT (1) IT1191049B (da)
NL (1) NL8204122A (da)
SE (1) SE8206055L (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU196230B (en) * 1983-12-29 1988-10-28 Chinoin Gyogyszer Es Vegyeszet Process for producing water-soluble forms of polyene antibiotics and pharmaceutics comprising such active ingredient and plant protective with antifungal effect
GB2162529B (en) * 1984-06-08 1988-03-02 Nitrokemia Ipartelepek B-cyclodextrin complex of benzene sulphonyl urea derivatives
US5223295A (en) * 1988-01-22 1993-06-29 Asterol International Process for the elimination of steroid compounds contained in substance of biological origin
US5229370A (en) * 1988-08-15 1993-07-20 Ammeraal Robert N Water soluble branched beta cyclodextrin steroid complex
EP0381747A4 (en) * 1988-08-15 1991-09-11 American Maize-Products Company Water soluble branched beta cyclodextrin steroid complex
EP0540751A4 (en) * 1991-05-20 1994-10-26 Eisai Co Ltd Steroid compound combined with polysaccharide
US20040152664A1 (en) * 1998-09-02 2004-08-05 Allergan, Inc. Prednisolone compositions
US20040048830A1 (en) * 2000-11-02 2004-03-11 Mingqiang Zhang Use of cortisol-sequestering agents for the treatment of hypercortisolaemia related disorders
EP1216712A1 (en) 2000-12-20 2002-06-26 Schering Aktiengesellschaft Cyclodextrin-drospirenone inclusion complexes
JP5350572B2 (ja) * 2000-12-20 2013-11-27 バイエル ファーマ アクチエンゲゼルシャフト シクロデキストリン−ドロスピレノン封入複合体
EP1216713A1 (en) 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
US12370352B2 (en) 2007-06-28 2025-07-29 Cydex Pharmaceuticals, Inc. Nasal and ophthalmic delivery of aqueous corticosteroid solutions
WO2013135248A2 (en) * 2012-03-13 2013-09-19 Amphidex A/S Production of stabilized channel type cyclodextrin crystals
IL327132A (en) * 2023-09-29 2026-05-01 Institut National De La Sant? Et De La Rech M?Dicale Eye drop formulations containing spironolactone

Also Published As

Publication number Publication date
DD208549A5 (de) 1984-04-04
IT1191049B (it) 1988-02-24
DK474782A (da) 1983-04-28
FR2515187A1 (fr) 1983-04-29
DE3238800A1 (de) 1983-05-05
IT8223942A0 (it) 1982-10-26
IT8223942A1 (it) 1984-04-26
GB2109381A (en) 1983-06-02
ES516840A0 (es) 1983-09-16
BE894825A (fr) 1983-02-14
JPS5883699A (ja) 1983-05-19
HU190356B (en) 1986-08-28
ES8308571A1 (es) 1983-09-16
SE8206055D0 (sv) 1982-10-25
SE8206055L (sv) 1983-04-28

Similar Documents

Publication Publication Date Title
Miranda et al. Cyclodextrins and ternary complexes: technology to improve solubility of poorly soluble drugs
Duchěne et al. Pharmaceutical uses of cyclodextrins and derivatives
Albers et al. Cyclodextrin derivatives in pharmaceutics
Schwarz et al. Solubilizing steroidal drugs by β-cyclodextrin derivatives
Bekers et al. Cyclodextrins in the pharmaceutical field
Waleczek et al. Phase solubility studies of pure (−)-α-bisabolol and camomile essential oil with β-cyclodextrin
Lahiani-Skiba et al. Solubility and dissolution rate of progesterone-cyclodextrin-polymer systems
Del Valle Cyclodextrins and their uses: a review
Medarević et al. Influence of hydrophilic polymers on the complexation of carbamazepine with hydroxypropyl-β-cyclodextrin
DE60117777T2 (de) Acylierte zyclodextrin guest-inklusion komplexe
Zoeller et al. Application of a ternary HP-β-CD-complex approach to improve the dissolution performance of a poorly soluble weak acid under biorelevant conditions
Arias et al. Investigation of the triamterene–β-cyclodextrin system prepared by co-grinding
FR2515187A1 (fr) Complexes d'inclusion de steroides avec de la g-cyclodextrine, procede pour leur preparation et compositions pharmaceutiques les contenant
Astakhova et al. Modern Drug Technologies: Synthesis, Characterization, and Use of Inclusion Complexes Between Drugs and Cyclodextrins (A Review).
Yu et al. Effect of camphor/cyclodextrin complexation on the stability of O/W/O multiple emulsions
Jagdale et al. Enhancement of dissolution of fenofibrate using complexation with hydroxy propyl β-cyclodextrin
Mendez-Ardoy et al. Monodisperse nanoparticles from self-assembling amphiphilic cyclodextrins: Modulable tools for the encapsulation and controlled release of pharmaceuticals
Yardy et al. Incorporation of loratadine-cyclodextrin complexes in oral thin films for rapid drug delivery
HU201783B (en) Process for producing partially methylized carboxy-acyl-beta-cyclodextrines and salts
Glomot et al. Improvement in availability and stability of a dermocorticoid by inclusion in β-cyclodextrin
JP2004516344A (ja) シクロデキストリン複合体の作成
Kurkov et al. Parenteral delivery of HPβCD: effects on drug-HSA binding
Zerrouk et al. Physical characteristics of inclusion compounds of 5-ASA in α and β cyclodextrins
Uzqueda et al. Characterization of Complexes Between Naftifine and Cyclodextrins in Solution and in the Solid State: Uzqueda et al.
US20080214497A1 (en) Water dispersible policosanol cyclodextrin complex and method of its production

Legal Events

Date Code Title Description
A85 Still pending on 85-01-01
BV The patent application has lapsed